Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rodeo Therapeutics

- PMLiVE

Amgen buoyant as profits rise in Q3

Increases 2012 revenue and earnings forecasts

Pharma deals during September 2012

In this regular review of deals we focus on transactions announced during September 2012

- PMLiVE

Amgen’s Anna Richo joins UCB as executive VP and general counsel

Meanwhile, Cynthia Patton takes over as Amgen’s senior VP and chief compliance officer

- PMLiVE

Merck & Co pays €110m upfront for AiCuris’ CMV portfolio

Lead candidate is orphan drug letermovir for transplant patients

- PMLiVE

Sanofi acquires Colombian pharma manufacturing firm Genfar

Expands its Latin American generics portfolio

- PMLiVE

AZ share buyback suspension prompts M&A speculation

Analysts query new CEO Pascal Soriot’s intention to preserve cash reserves

Novartis building

Novartis signs $665m option deal with Selexys

Would acquire biotech company and its sickle cell disease drug

- PMLiVE

Bayer buys Teva animal health unit

Deal valued at $145m

Amgen poaches J&J’s Ray Jordan for corporate affairs post

He joins on October, 1 with a strategic communications remit

- PMLiVE

Merck KGaA acquires cancer drug from Symphogen

Will pay up to €495m for investigational metastatic colorectal cancer treatment

- PMLiVE

Pharma deals during August 2012

In this regular review of deals we focus on transactions announced during August 2012

Valeant offers $2.6bn to buy dermatology firm Medicis

Possible further addition to long list of Canadian pharma firm’s acquisitions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links